sotalol or class I agents for maintenance of SR in AF, 13 and is particularly effective in rheumatic AF patients after mitral valve (MV) surgery 3 or PTMV. 4, 5 However, the longterm use of amiodarone, even at a low dose, can cause a variety of side-effects including abnormal thyroid function, arrhythmias, and serious pulmonary firosis. 14 In light of its potential adverse effects, it is important to identify patients who, in need of post PTMV restoration of SR, would benefit from long-term amiodarone therapy. Duration of AF has been implicated by some studies to be the only predictor of acute and long-term success. 4, 5 However, the degree of atrial remodeling in rheumatic AF may differ among individuals, and it is not certain whether duration of AF should be the only factor to consider when contemplating the use of rhythm control therapy for this group of patients. In order to answer this question, the present study sought to identify the predictors of successful maintenance of SR in patients with rheumatic AF who underwent PTMV and then amiodarone therapy and cardioversion.
Methods

Patients
From January 2000 to December 2002, we recruited 23 consecutive patients with rheumatic AF who had undergone PTMV. The duration of AF in patients varied. In all patients, transthoracic echocardiographic examinations were performed using a 2. Hewlett-Packard, Palo Alto, CA, USA) to measure MV area, pressure gradient, and valvular regurgitation immediately before PTMV and again 1 day after the procedure. LA diameter was measured during the diastolic phase using M-mode study in the parasternal long-axis view following procedures recommended by the American Association of Echocardiography. The Doppler pressure half time method was used to calculate MV area, as this method has been shown to reliably assess the effects of PTMV. 15 Patients were excluded from the study if they had a prior history of cardioversion, a MV Wilkins score 16 less than or equal 8, heavily calcified MVs, significant mitral, tricuspid, or aortic regurgitation, significant aortic stenosis, LA thrombus (detected by transesophageal echocardiography), or contraindications to anticoagulants and amiodarone. PTMV was performed using an Inoue balloon (Toray Medical Corporation, Tokyo, Japan) and the transseptal approach. 17 LA pressure was recorded before and after PTMV. All patients gave informed written consent and all procedures followed institutional ethical standards and guidelines.
Study Protocol
Eight of the patients with AF first received oral amiodarone (Cordarone ® , Sanofi Aventis) for 2 months (400 mg/day for 1 month followed by 200 mg/day) before undergoing PTMV. Immediately after PTMV, each of these 8 patients underwent direct current external cardioversion using a Hewlett-Packard defibrillator (model 1771A/B Code Mater XL+) to restore SR. The other 15 AF patients first received PTMV and were then administered amiodarone at similar dosages for 2 months. If AF persisted, they underwent electrical cardioversion. All 23 patients were then kept on amiodarone 200 mg/day after restoration of SR by cardioversion.
All patients were taking warfarin (Coumarin ® , BristolMyers Squibb). We adjusted the dosages of this agent at least 4 weeks before the procedure to ensure adequate anticoagulation (international normalized ratio between 2.0 and 3.0). All patients fasted through the night before they underwent electrical cardioversion. Before the procedure, they were administered intravenous midazolam (Versed ® , Roche Laboratories) or diazepam (Valium ® , Roche Laboratories) for sedation and meperidine 50 mg (Demerol ® , Sanofi Aventis) for analgesia.
After the procedure, patients were followed up at our outpatient clinic on a monthly basis. Patients who remained in SR at the 3-and 6-month follow-ups underwent Doppler echocardiographic examinations to determine whether atrial transport function had been restored. Doppler transmitral ≥25 cm/s and transtricuspid ≥15 cm/s atrial waves were considered indicative of effective restoration of atrial transport function.
Statistical Analysis
Continuous variables are presented as mean ± SD, and differences between the patients with SR maintained and the patients with a recurrence of AF at 1-year follow-up were compared using Student's t-test or Wilcoxon rank sum test. Because electrical cardioversion was required for conversion to SR in all patients regardless of whether they had received amiodarone before PTMV or after and because the clinical characteristics did not differ between groups, all 23 study patients were considered as 1 group for statistical analysis. Categorical variables were compared using Chi-square or Fisher's exact test. Stepwise discriminate analysis was performed to study the relationship between binary outcome and multiple continuous and categorical determinants. Statistical analysis was performed using a statistical software program (SAS version 8.02; SAS Institute, Cary, NC, USA). A p-value <0.05 was considered significant. Table 1 summarizes the clinical characteristics and echocardiographic parameters of all study patients. As can be seen, this was a high-risk group of patients with 39% having a history of stroke.
Results
PTMV resulted in significant increases in MV area, decreases in LA diameter and pressure, increases in left ventricular ejection fraction (LVEF), decreases in MV pressure gradient and slight increases in mitral regurgitation ( Table 2) .
The 8 patients who received amiodarone for 2 months before PTMV, as well as the 15 patients who received it for 2 months after PTMV, remained in AF. In all 23 patients SR was successfully restored only after electrical cardioversion.
Based on the finding of our follow-up (mean 35±8 months), 9 (39%) patients had a recurrence of AF within 1 year (Fig 1) . The remaining 14 (61%) patients were in SR at the 24-month follow-up. Eight of these 14 patients who had been followed up for more than 30 months continued to be in SR.
We compared the characteristics of the patients in whom AF had recurred within 1 year with those in whom SR had been maintained for 24 months (Table 3 ). Univariate analysis showed that decreases in LA size (p<0.004) and increases in MV area (p<0.01) by PTMV were associated with maintenance of SR. Age, AF duration, LA size before and after PTMV, LVEF, MV area, mitral regurgitation, MV pressure gradient and LA pressure were not associated with the clinical outcome. In multivariate stepwise discriminate analysis, the degree of reduction in LA size (p=0.004) and of increase in MV area (p=0.01) remained significant independent predictors for the maintenance of SR at 24-month follow-up. The sensitivity and specificity of the cutoff value of LA diameter reduction ≥3 mm were 71% and 100%, respectively, and the corresponding cutoff values for MV area increase ≥0.7 cm 2 were 64% and 89%. At the 3-month follow-up, effective transmitral (not shown) and transtricuspid atrial waves were observed in all patients, except for 1, who remained in SR, but had restored atrial transport function at the 6-month follow-up.
Administration of amiodarone did not cause significant side-effects in pulmonary, gastrointestinal and neurological functioning in any of patients except in 3 patients. In 1, there were mild increases in thyroid stimulating hormone and normal free thyroxine level; in the other 2, there were mild elevations of liver enzymes. Once the amiodarone dose was reduced to 100 mg/day, the side-effects subsided and SR was maintained.
Discussion
This study has 2 major findings. First, although amiodarone alone fails to convert AF to SR before or after PTMV, SR can be restored and maintained in patients with rheumatic AF if they receive amiodarone and electrical cardioversion following PTMV reduction of mitral stenosis and LA size. With this approach, 61% of our patients with rheumatic AF remained in SR for more than 24-months at follow-up. Second, the degree of increase in MV area and reduction in LA size by PTMV were found to be significant determinants for successful maintenance of SR in these patients.
Predictors of Successful Maintenance of SR in Rheumatic AF After PTMV
Few studies have specifically examined the factors determining the successful maintenance of SR in patients with rheumatic AF. [2] [3] [4] [5] In patients who have valvular surgery, the duration of AF and LA size have been found to be important in identifying those who would probably have SR restored and maintained over 1-2 years of follow-up 2,3 and administration of amiodarone combined with electrical cardioversion has been found to improve the outcome. 3 Univariate analysis in 2 studies 4,5 of PTMV in rheumatic AF patients receiving amiodarone and electrical cardioversion also indicated the significance of the duration of AF and baseline LA size in determining the restoration and maintenance of SR. However, multivariate analysis showed the duration of AF to be the only significant predictor in long-term maintenance of SR. The studies did not examine the significance of changes in LA size or MV area. In our study, multivariate analysis did not find patient age, duration of AF, baseline LVEF, LA size and pressure, MV area, mitral regurgitation, or pressure gradient across the MV to be predictive of successful maintenance of SR. Instead, it revealed that there were only 2 significant factors associated with the successful maintenance of SR: increase in the MV area and decrease in the LA size by PTMV. These findings are consistent with those of a recent study 18 in which atrial size reduction, not AF duration or preoperative atrial size, was found to predict the success of conversion and maintenance of SR in rheumatic AF patients undergoing concomitant radiofrequency maze procedure and valvular surgery.
Reduction of the LA size (p=0.004) was found to be the most significant independent predictor for maintenance of SR in this study. Of particular interest, the present patients with recurrence of AF experienced a reduction in LA pressure by PTMV similar to that in the patients without such recurrence (Table 3) . They did, however, experience a smaller reduction in LA size by PTMV. The patients with recurrence of AF had a significantly greater ratio of change in LA pressure to change in LA diameter than in patients whose SR were found to be maintained after 1 year (5.0± 5.0 mmHg/mm vs 1.0±0.9 mmHg/mm, p<0.02), suggesting that the patients with a recurrence of AF had less compliant and possibly more advanced pathological changes in the LA and may, as a result, not be good candidates for rhythm control. Our findings suggest that rheumatic AF patients whose LA diameter can be decreased ≥3 mm by PTMV may benefit from post-procedure amiodarone and electrical cardioversion for maintenance of SR.
Time Course of Restoration of Atrial Mechanical Function
Depending on the duration of AF, atrial size and underlying heart disease, recovery of atrial mechanical function after cardioversion of AF may take from 1 to 4 weeks. [19] [20] [21] The present patients probably had severe pathophysiological changes in the atria, as atrial transport function in 1 of them was not observed at 3 months, but became evident at 6 months. As suggested by the AFFIRM study, 22 all of the patients remained on warfarin after cardioversion, regardless of whether SR was maintained or not, because they may still be at relatively high risk of stroke.
Study Limitations
First, the time course of changes in MV area and LA size was not systemically followed, as recurrence of AF may be caused by restenosis of the MV. Second, our cohort was small, which may limit the statistical power to detect differences between groups. Third, the duration of AF was based on documentation of ECG and may, therefore, have been underestimated and may have influenced the patients' decision whether or not to undergo cardioversion after PTMV. This may partly explain the different results between other studies 4, 5 and ours. Fourth, the follow-up period was relatively short and serious adverse side-effects of amiodarone may not have been evident. 14 Fifth, we did not randomize these patients for receiving amiodarone after DC cardioversion because amiodarone has been shown to be effective for maintenance of SR in AF patients. 4 ,5,13 Therefore, it is likely, but not certain, that amiodarone may have helped maintain SR in the patients after DC cardioversion. Sixth, we did not compare our strategy for treating AF with catheter ablation. Catheter ablation is seldom performed in rheumatic AF patients, 23 but in those studies that have used it, the success rate was limited. 11, 12 The intra-operative radiofrequency maze procedure 18 is an option only for patients undergoing concomitant open-heart surgery for MV replacement. Thus, the strategy we studied here represents a feasible alternative treatment option in select patients after PTMV and may be justified in patients subject to the possible risk of sideeffects from long-term amidarone use, because AF can be converted to SR and the risk of thromboembolism can be reduced.
Conclusion
Regardless of the length of time a patient has had rheumatic AF, the successful maintenance of SR with amiodarone and electrical cardioversion can be predicted by the degree to which LA size is reduced and MV area is increased.
